Tumor Suppressors RB1 and CDKN2a Cooperatively Regulate Cell-Cycle Progression and Differentiation During Cardiomyocyte Development and Repair.

Abstract

RATIONALE:

Although rare cardiomyogenesis is reported in the adult mammalian heart, whether this results from differentiation or proliferation of cardiomyogenic cells remains controversial. The tumor suppressor genes RB1 (retinoblastoma) and CDKN2a (cyclin-dependent kinase inhibitor 2a) are critical cell-cycle regulators, but their roles in human cardiomyogenesis remains unclear.

OBJECTIVE:

We hypothesized that developmental activation of RB1 and CDKN2a cooperatively cause permanent cell-cycle withdrawal of human cardiac precursors (CPCs) driving terminal differentiation into mature cardiomyocytes, and that dual inactivation of these tumor suppressor genes promotes myocyte cell-cycle reentry.

METHODS AND RESULTS:

Directed differentiation of human pluripotent stem cells (hPSCs) into cardiomyocytes revealed that RB1 and CDKN2a are upregulated at the onset of cardiac precursor specification, simultaneously with GATA4 (GATA-binding protein 4) homeobox genes PBX1 (pre-B-cell leukemia transcription factor 1) and MEIS1 (myeloid ecotropic viral integration site 1 homolog), and remain so until terminal cardiomyocyte differentiation. In both GATA4+ hPSC cardiac precursors and postmitotic hPSC-cardiomyocytes, RB1 is hyperphosphorylated and inactivated. Transient, stage-specific, depletion of RB1 during hPSC differentiation enhances cardiomyogenesis at the cardiac precursors stage, but not in terminally differentiated hPSC-cardiomyocytes, by transiently upregulating GATA4 expression through a cell-cycle regulatory pathway involving CDKN2a. Importantly, cytokinesis in postmitotic hPSC-cardiomyocytes can be induced with transient, dual RB1, and CDKN2a silencing. The relevance of this pathway in vivo was suggested by findings in a porcine model of cardiac cell therapy post-MI, whereby dual RB1 and CDKN2a inactivation in adult GATA4+ cells correlates with the degree of scar size reduction and endogenous cardiomyocyte mitosis, particularly in response to combined transendocardial injection of adult human hMSCs (bone marrow-derived mesenchymal stromal cells) and cKit+ cardiac cells.

CONCLUSIONS:

Together these findings reveal an important and coordinated role for RB1 and CDKN2a in regulating cell-cycle progression and differentiation during human cardiomyogenesis. Moreover, transient, dual inactivation of RB1 and CDKN2a in endogenous adult GATA4+ cells and cardiomyocytes mediates, at least in part, the beneficial effects of cell-based therapy in a post-MI large mammalian model, a finding with potential clinical implications.

• Authors: Konstantinos E Hatzistergos, Adam R Williams, Derek Dykxhoorn, Michael A Bellio, Wendou Yu, Joshua M Hare
• Journal: Circulation research (Circ Res) Vol. 124 Issue 8 Pg. 1184-1197 (04 12 2019) ISSN: 1524-4571 [Electronic] United States
• PMID: 30744497 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• GATA4 Transcription Factor
• GATA4 protein, human
• MEIS1 protein, human
• Myeloid Ecotropic Viral Integration Site 1 Protein
• Pre-B-Cell Leukemia Transcription Factor 1
• PBX1 protein, human

Topics

• Animals
• Cell Cycle (physiology)
• Cell Differentiation (physiology)
• Cell Line
• GATA4 Transcription Factor (genetics, metabolism)
• Gene Silencing
• Genes, Retinoblastoma (physiology)
• Genes, p16 (physiology)
• Humans
• Induced Pluripotent Stem Cells (cytology, physiology)
• Myeloid Ecotropic Viral Integration Site 1 Protein (genetics, metabolism)
• Myocytes, Cardiac (physiology)
• Pluripotent Stem Cells (transplantation)
• Pre-B-Cell Leukemia Transcription Factor 1 (genetics, metabolism)
• Swine
• Up-Regulation